NASDAQ:OASM Oasmia Pharmaceutical AB (publ) (OASM) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free OASM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.02▼$0.0250-Day Range$1.30▼$1.6252-Week Range$0.94▼$5.70Volume250 shsAverage Volume98,414 shsMarket Capitalization$1.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Oasmia Pharmaceutical AB (publ) alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Oasmia Pharmaceutical AB (publ)Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.Read More Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… OASM Stock News HeadlinesMarch 23, 2024 | morningstar.comLipigon Pharmaceuticals AB LPGOMarch 6, 2024 | gurufocus.comLSK BioPartners, Inc., Oasmia Pharmaceutical AB (publ) - Special Call TranscriptMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 6, 2024 | gurufocus.comOasmia Pharmaceutical AB (publ) - Special Call TranscriptFebruary 8, 2024 | finance.yahoo.comResurs Holding AB (publ) (RESURS.ST)January 6, 2024 | morningstar.comQuiaPEG Pharmaceuticals Holding AB QUIANovember 29, 2023 | investing.comNewbury Pharmaceuticals AB (NEWBRY)September 14, 2023 | investing.comLipigon Pharmaceuticals AB (LPGO)March 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.August 25, 2023 | investing.comSpeqta publ AB (SPEQT)August 25, 2023 | seekingalpha.comPRXXF Paradox Interactive AB (publ)February 26, 2023 | seekingalpha.comOXE Marine AB (publ) Non-GAAP EPS of -SEK0.43, revenue of SEK32.2MMarch 11, 2022 | stockhouse.comOrexo appoints Fredrik Järrsten as new CFONovember 29, 2021 | finanznachrichten.deNotice of extra general meeting in Terranet ABJuly 22, 2021 | investing.comFancy Wood Industries PCL (FANCY)See More Headlines Receive OASM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oasmia Pharmaceutical AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:OASM CUSIPN/A CIK1607245 Webwww.oasmia.com Phone(461) 850-5440FaxN/AEmployees57Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,950,000.00 Net Margins-8,633.64% Pretax MarginN/A Return on Equity-43.94% Return on Assets-28.92% Debt Debt-to-Equity RatioN/A Current Ratio0.80 Quick Ratio0.73 Sales & Book Value Annual Sales$220,000.00 Price / Sales6.82 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book0.03Miscellaneous Outstanding Shares74,967,000Free FloatN/AMarket Cap$1.50 million OptionableNot Optionable Beta0.96 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesFrançois R. MarteletChief Executive OfficerFredrik JärrstenChief Financial OfficerMikael AspChief Technology OfficerNigel GoodmanDirector-Clinical OperationsCarina EklöwDirector-Global Medical AffairsKey Competitors60 Degrees PharmaceuticalsNASDAQ:SXTPDermata TherapeuticsNASDAQ:DRMASunshine BiopharmaNASDAQ:SBFMCyclacel PharmaceuticalsNASDAQ:CYCCHistogenNASDAQ:HSTOView All Competitors OASM Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Oasmia Pharmaceutical AB (publ) own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oasmia Pharmaceutical AB (publ) investors own include G1 Therapeutics (GTHX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Supernus Pharmaceuticals (SUPN), Verastem (VSTM), Akari Therapeutics (AKTX), Nightstar Therapeutics (NITE), Novavax (NVAX) and OpGen (OPGN). This page (NASDAQ:OASM) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe 3rd Revolution in WarfareWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oasmia Pharmaceutical AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.